Clinical efficacy of insulin detemir combined with repaglinide in the treatment of type 2 diabetes mellitus / 中国基层医药

ABSTRACT

Objective To analyze the clinical effect of insulin detemir combined with repaglinide in the treatment of type 2 diabetes mellitus (T2DM).Methods From January 2016 to July 2017,100 patients with T2DM in the First People＇s Hospital of Jiande were randomly divided into the observation group and control group according to the digital table,with 50 cases in each group.The control group was treated by low neutral protamine zinc human insulin( N) and repaglinide,the observation group was treated by insulin detemir combined with repaglinide .The clinical treatment effect was compared between the two groups.Results The total effective rate of the observation group was 96%,which was significantly higher than 78% of the control group,the difference was statistically signifi-cant (χ2＝22.014,P＜0.05).Before treatment,the biochemical indicators between the two groups had no statistically significant differences (t ＝0.125,1.225,0.125,1.225,0.142,all P ＞0.05).After treatment,the biochemical indicators of the observation group were better than those of the control group (t ＝5.064,5.035,5.064,5.035,5.165,all P ＜0.05 ).Conclusion Though insulin detemir combined with repaglinide and traditional insulin combined with repaglinide can lower blood glucose in patients with T 2DM,but the former combination effect is better.